InspireMD (NSPR) Net Cash Flow Growth (3y) (2013 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 42.74% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -87.88% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -48.90% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 129.29% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -65.12% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 33.47% |
| 10 | InspireMD | 64.01 Mn | 9.80 Mn | 1.18 Mn | -332.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -332.39% |
| Sep 30, 2025 | 184.94% |
| Jun 30, 2025 | 11.08% |
| Mar 31, 2025 | -16.18% |
| Dec 31, 2024 | 69.64% |
| Sep 30, 2024 | 23.72% |
| Jun 30, 2024 | 34.63% |
| Mar 31, 2024 | -26.16% |
| Dec 31, 2023 | -63.72% |
| Sep 30, 2023 | 40.61% |
| Jun 30, 2023 | -68.90% |
| Mar 31, 2023 | 45.46% |
| Dec 31, 2022 | 34.32% |
| Sep 30, 2022 | -45.06% |
| Jun 30, 2022 | -8.03% |
| Mar 31, 2022 | -5.52% |
| Dec 31, 2021 | 15.93% |
| Sep 30, 2021 | -99.84% |
| Jun 30, 2021 | -50.71% |
| Mar 31, 2021 | 223.68% |
| Dec 31, 2020 | 54.14% |
| Sep 30, 2020 | -12.57% |
| Jun 30, 2020 | 101.95% |
| Mar 31, 2020 | -61.37% |
| Dec 31, 2019 | 17.85% |
| Sep 30, 2019 | -37.60% |
| Jun 30, 2019 | 3.87% |
| Mar 31, 2019 | -41.59% |
| Dec 31, 2018 | 18.01% |
| Jun 30, 2018 | 36.37% |
| Mar 31, 2018 | -48.87% |
| Mar 31, 2017 | 31.61% |
| Sep 30, 2016 | 69.11% |
| Jun 30, 2016 | -28.43% |
| Mar 31, 2016 | 24.38% |
| Dec 31, 2015 | -3.00% |
| Mar 31, 2015 | 81.96% |
| Mar 31, 2014 | -34.35% |
| Sep 30, 2013 | -112.28% |